William Oneill, MD
Cardiovascular Disease · Naples, FLNPI 1881676435
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $395,175 of the $637,265 with a category attached, or 62.0%. Abiomed accounts for 77.8% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $217,599 and has fallen 79.3% since, to $44,961 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 506 payments — averaging $1259.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$495K
- ZOLL Circulation Inc$49K
- Abbott$26K
- Tendyne Holdings, Inc.$20K
- Boston Scientific$16K
- Bard Peripheral Vascular, Inc.$15K
- plus $16K from 12 others
Across 463 payments — averaging $8672.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$3M
- ZOLL Circulation Inc$446K
- Boston Scientific$404K
- Abbott$94K
- Medtronic$28K
- Abiomed$10K
- plus $5K from 1 others
What the payments were for
- Consulting fees$94,59915%
- Speaking & faculty fees$395,17562%
- Grants$2,5850%
- Travel & lodging$106,02917%
- Food & beverage$18,9123%
- Other$19,9663%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 279 | $495,481 |
| ZOLL Circulation Inc | 42 | $49,302 |
| Abbott | 42 | $26,134 |
| Tendyne Holdings, Inc. | 1 | $19,685 |
| Boston Scientific | 36 | $16,085 |
| Bard Peripheral Vascular, Inc. | 14 | $14,819 |
| Edwards Lifesciences | 71 | $12,192 |
| Cardiovascular Systems Inc. | 7 | $1,980 |
| Angiodynamics, Inc. | 2 | $539 |
| Medtronic(2 entities) | 3 | $292 |
| Teleflex LLC | 1 | $175 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $125 |
| Shockwave Medical, Inc | 1 | $123 |
| Amgen | 2 | $111 |
| Heartflow, Inc. | 1 | $96 |
| Inari Medical, Inc. | 1 | $78 |
| Siemens Medical Solutions USA, Inc. | 1 | $27 |
| Philips North America LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$484,042
- TherOx DS2 Console$48,915
- Catheter$48,915
- Downstream Cartridge$48,915
- AMPLATZER Occluders$24,682
- Edwards SAPIEN 3 Transcatheter Heart Valve$8,317
- GENERAL - STRUCTURAL HEART$7,112
- LOTUS EDGE$3,123
- GENERAL - THERAPIES$3,081
- Coronary Orbital Atherectomy System$1,586
- Watchman$1,125
- Pristine$773
- SAPIEN 3 Ultra RESILIA$639
- PORTICO$578
- AngioVac$539
- PASCAL$497
- Lutonix Drug Coated Balloon$367
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$273
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$212
- Apollo$179
How this compares
$637,265 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $18,762 |
| Repatha SureclickEvolocumab | 12 | $14,158 |
| Repatha SyringeEvolocumab | 12 | $12,186 |
| Repatha PushtronexEvolocumab | 19 | $10,786 |
| Ranolazine ErRanolazine | 11 | $1,718 |
| ClopidogrelClopidogrel Bisulfate | 53 | $957 |
| Bumetanide | 11 | $684 |
| Ezetimibe | 24 | $569 |
| Potassium Chloride | 17 | $537 |
| Metoprolol Succinate | 19 | $351 |
| Atorvastatin Calcium | 26 | $314 |
| Digoxin | 11 | $258 |
| Rosuvastatin Calcium | 13 | $238 |
| Furosemide | 12 | $78 |
| Losartan Potassium | 11 | $61 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Naples
- Dee Dee WangNaples$173K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.